好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying the “Sweet Spot” for GPI DBS Programming
Movement Disorders
P2 - Poster Session 2 (11:45 AM-12:45 PM)
3-012
To determine the ideal location for deep brain stimulation (DBS) of globus pallidus interna (GPi) in Parkinson’s Disease (PD).
The clinical success of DBS is dependent on accurate electrode placement and stimulation of a specific region within brain targets including GPi. There is a knowledge gap on location of the ideal stimulation area within GPi, hence identifying this could facilitate DBS programming and improve surgical outcomes.

All patients who underwent GPi DBS between 2020-2022 were included in the study and their clinical and imaging data were retrospectively analyzed. Stimulation data at six months post-op was used to generate stimulation field model (SFM) for each lead with Boston Scientific GUIDE™ XT and then aggregated to generate volumetric stimulation heatmaps with BrainLab Quentry® software. Clinical Global Impression-Change (CGI-C) scale was the primary outcome measure, scored according to response in contralateral tremor, rigidity and bradykinesia, and then correlated with SFM to generate ideal locations for stimulation in GPi. The secondary outcome measure was difference in pre- and post-DBS MDS-UPDRS scores.

Twenty-two PD patients with 36 GPi leads were included in the study. Mean age was 64±8.5 and 67% were male. MDS-UPDRS improved from 33.5 to 19.7 (42%) six months post-op (p=0.0003). For right GPi leads, 11/16 (69%) had CGI-C of 1 (very much improved) and 5/16 (31%) had 2 (much improved). For left GPi leads 13/20 (65%) and 7/20 (35%) had CGI-C of 1 and 2, respectively. We identified the “sweet spot” corresponding with CGI-C of 1 to be in the postero-lateral and middle region of GPi on axial and coronal sequences, respectively.

In this single-center study we identified that stimulation in the postero-lateral and middle region of GPi resulted in the best clinical outcomes. Our findings support the previously reported, limited evidence in literature and therefore will have important therapeutic implications.
Authors/Disclosures
Lubna Jafri, MD, MBBS (Wake Forest Baptist Health)
PRESENTER 		Dr. Jafri has nothing to disclose.
Jessica Tate, MD (Atrium Health Wake Forest Baptist) The institution of Dr. Tate has received research support from Ipsen. The institution of Dr. Tate has received research support from Boston Scientific. The institution of Dr. Tate has received research support from Revance Therapeutics. The institution of Dr. Tate has received research support from CHDI Foundation. The institution of Dr. Tate has received research support from NINDS. The institution of Dr. Tate has received research support from Michael J. Fox Foundation.
Mary Ann Thenganatt, MD (Atrium Health Wake Forest Baptist) Dr. Thenganatt has nothing to disclose.
Deepal P. Shah-Zamora, MD (Atrium Health Wake Forest Baptist) Dr. Shah-Zamora has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Winthrop Industrie. The institution of Dr. Shah-Zamora has received research support from CereGate Inc. The institution of Dr. Shah-Zamora has received research support from Amneal. The institution of Dr. Shah-Zamora has received research support from AbbVie .
Adrian Laxton No disclosure on file
Stephen B. Tatter, MD (Wake Forest Univ School of Medicine) The institution of Dr. Tatter has received research support from Monteris Medical, Inc. The institution of Dr. Tatter has received research support from Arbor Pharmaceuticals. Dr. Tatter has received intellectual property interests from a discovery or technology relating to health care.
Mustafa S. Siddiqui, MD, FAAN Dr. Siddiqui has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific Neuromodulation. Dr. Siddiqui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Siddiqui has received research support from Boston Scientific Neuromodulation. The institution of Dr. Siddiqui has received research support from Abbvie. The institution of Dr. Siddiqui has received research support from National Institute of Health .